Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

IL-1ra and olanzapine induced adverse metabolic reaction

A technology for olanzapine and abnormal metabolism, which is applied in the field of pharmacology and molecular detection, and can solve the problems of unclear internal mechanism of pathophysiological process of metabolic side effects, drug mixing, etc.

Active Publication Date: 2019-06-11
SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there are many hypotheses about how olanzapine causes metabolic side effects, but the pathophysiological process and internal mechanism of olanzapine-induced metabolic side effects are not very clear, and the reasons may be related to H1,5-HT,D2,M2 , M3 receptor-related
In recent years, cytokines and metabolic adverse reactions induced by second-generation antipsychotic drugs have received more and more attention, but most of the current studies focus on one or a few factors, and most of the drugs are mixed, and rarely single drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • IL-1ra and olanzapine induced adverse metabolic reaction
  • IL-1ra and olanzapine induced adverse metabolic reaction
  • IL-1ra and olanzapine induced adverse metabolic reaction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0185] General information and clinical characteristics of the patient group and healthy controls

[0186] In this study, there was no significant difference in age and gender between patients with schizophrenia and healthy controls. See Table 2 for detailed demographic data and clinical characteristics. During the 8-week antipsychotic treatment, the antipsychotic drugs used in the follow-up period of 23 schizophrenic patients were all olanzapine (23 cases). All patients received olanzapine monotherapy, only 2 patients took zopiclone, 1 patient took clonazepam, and 1 patient took lorazepam. The total score of PANSS in patients with schizophrenia before treatment was 75.64±18.32, and the total score of PANSS decreased to 44.77±11.98 after treatment (p=0.000). The reduction rate of PANSS was defined as (total baseline score before treatment-total score after treatment) / (total baseline score-30)×100%. Taking the PANSS score reduction rate ≥ 25% as the standard of effective trea...

Embodiment 2

[0193] Comparison of Cytokine Levels in Healthy Controls and Patients with Schizophrenia Before Treatment

[0194] Pre-treatment cytokine levels were compared between healthy controls and schizophrenia patients using the methods described in General Methods.

[0195] The result is as figure 2 and shown in Table 3.

[0196] Table 3. Comparison of factor levels in patients with schizophrenia at baseline and in healthy controls

[0197]

[0198] Variables are represented by median (minimum-maximum)

[0199] a Two independent samples T-test

[0200] b Rank sum test for two independent samples

[0201] *(p<0.05)

[0202] figure 2 Combined with the data in Table 3, the levels of IL-1ra (P=0.0001), MCP-1 (P=0.003), and VEGF (P=0.014) were significantly increased in patients with schizophrenia compared with the normal control group before treatment. There was no significant difference in the levels of other cytokines between the SZ group and the HC group.

Embodiment 3

[0204] Comparison of metabolic indexes and cytokine levels in patients with schizophrenia before and after olanzapine treatment

[0205] Using the methods described in General Methods, the levels of metabolic indicators and cytokines were compared before and after olanzapine treatment in patients with schizophrenia.

[0206] The results are shown in Table 4 and Table 5.

[0207] Table 4. Changes of metabolic indicators in patients with schizophrenia before and after olanzapine treatment

[0208]

[0209]

[0210] aRepeated measures analysis of variance

[0211] b Friedman rank sum test

[0212] *(p<0.05)

[0213] Table 5. Comparison of cytokine levels in patients with schizophrenia before and after treatment

[0214]

[0215] aRepeated measures analysis of variance

[0216] b Friedman test

[0217] *(p<0.05)

[0218] Combination of Table 4 and Table 5 image 3 , Figure 4 The data showed that after 8 weeks of olanzapine treatment in patients with schizophreni...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides uses of IL-1ra and detection reagent thereof, and specifically provides an use of the interleukin 1 antagonist (IL-1ra) or a detection reagent thereof for preparing a diagnostic reagent or a diagnostic kit. The diagnostic reagent or kit is used for determining whether schizophrenia patients are suitable for treatment with olanzapine. The present invention also provides the corresponding detection kit and a detection method.

Description

technical field [0001] The present invention relates to the fields of pharmacology and molecular detection, and more specifically relates to IL-1ra and its application in predicting adverse metabolic reactions induced by olanzapine. Background technique [0002] Schizophrenia (SZ) is a severe, highly prevalent, highly relapsing, chronic and disabling mental disease that mostly occurs in young adults, and its lifetime incidence is about 1% of the world's population. Suffering from schizophrenia not only affects the patient's quality of life and family relationships, but also imposes a serious burden on the social economy. The mortality rate of this disease is 2-3 times higher than that of the general population, and the life expectancy is shortened by 10-20 years compared with the general population. About 60% of the observed higher mortality in schizophrenia than in the general population is attributable to physiological comorbidities, especially cardiovascular disease (CVD...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883G01N33/68
Inventor 崔东红林晔喆彭延敏粟幼嵩
Owner SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com